Build your own


Good Medicine is based on proof, but real conditions can make the difference. Let us help you build your own evidence and provide the best care for your patients.

Log in

Please enter your ID

Ileana HockingIleana
Ken BullockKen
The Heart Beat Clinicheartbeat
Estudio CohorteCOHORTE
Demo Salesdemosales
Demo Customerdemocustomer
Newtech ItaliaNewtech
Medsafe LatamMedsafe
Novamedical PortugalNovamedical
cudbein Brazilcudbein
UKB Registryukb
Todd WhetselTodd

Study of Syncope and Rare Palpitations

Hospital Virgen de los Lirios. Alcoy (Spain). Gómez Pastor et al. Sociedad Valenciana de Cardiología


42% of diagnostic yield in patients with syncopal episodes. Syncope of cardiogenic origin in 15% of patients and 27% with the exclusion of cardiogenic syncope *.



“The incorporation of Nuubo into the diagnostic algorithm of cardiogenic syncope represents a step forward in the management of this disease because it provides remarkable diagnostic efficacy at a lower cost compared to more classic options.  73% Reduction the use of ILR.”

2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope

Class IIa

To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, the external cardiac monitors can be useful.

Although the diagnostic yield of an external loop recorder may be lower than that of an implantable cardiac monitor, the non-invasive strategy is reasonable as a first approach.

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

Class I

Ambulatory electrocardiograhic monitoring is useful to evaluate whether symptoms, including palpitations, presyncope, or syncope, are caused by ventricular arrhythmias.

Atrial Fibrillation Detection After Stroke

Wearable Holter for AF detection in high risk patients after cryptogenic stroke (CRYPTO-AF).Pagola, J. et al. International Journal of Cardiology, Volume 251


21% of patients had an Atrial Fibrillation episode detected with Nuubo in the 30 days after the cryptogenic stroke*.



“Following our results, prolonged monitoring should be started immediately and maintained the first 4 weeks after stroke onset avoiding any delay and any gap. 28-day Holter monitoring from the acute phase of the stroke was feasible with Nuubo”

AHA / ASA GUIDELINE 2014 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Class IIa

For patients who have experienced an acute ischemic stroke or TIA with no other apparent cause, prolonged rhythm monitoring (≈30 days) for AF is reasonable within 6 months of the index event.


Dr. Pagola

11 Min is propriety of Nuubo.